299 related articles for article (PubMed ID: 16788764)
21. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma.
Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T
Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):76-80. PubMed ID: 15209547
[TBL] [Abstract][Full Text] [Related]
22. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
23. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2008 Aug; 86(2):362-6; discussion 366-7. PubMed ID: 18640297
[TBL] [Abstract][Full Text] [Related]
24. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
[TBL] [Abstract][Full Text] [Related]
25. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
26. Prognostic heterogeneity in multilevel N2 non-small cell lung cancer patients: importance of lymphadenopathy and occult intrapulmonary metastases.
Sakao Y; Okumura S; Mun M; Uehara H; Ishikawa Y; Nakagawa K
Ann Thorac Surg; 2010 Apr; 89(4):1060-3. PubMed ID: 20338307
[TBL] [Abstract][Full Text] [Related]
27. Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer.
Yildizeli B; Fadel E; Mussot S; Fabre D; Chataigner O; Dartevelle PG
Eur J Cardiothorac Surg; 2007 Jan; 31(1):95-102. PubMed ID: 17126556
[TBL] [Abstract][Full Text] [Related]
28. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis.
Matsuguma H; Nakahara R; Igarashi S; Ishikawa Y; Suzuki H; Miyazawa N; Honjo S; Yokoi K
J Thorac Cardiovasc Surg; 2008 Jan; 135(1):44-9. PubMed ID: 18179917
[TBL] [Abstract][Full Text] [Related]
29. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
[TBL] [Abstract][Full Text] [Related]
31. Is lobe-specific lymph node dissection appropriate in lung cancer patients undergoing routine mediastinoscopy?
Turna A; Solak O; Kilicgun A; Metin M; Sayar A; Gürses A
Thorac Cardiovasc Surg; 2007 Mar; 55(2):112-9. PubMed ID: 17377865
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung.
Fukai R; Sakao Y; Sakuraba M; Oh S; Shiomi K; Sonobe S; Saitoh Y; Miyamoto H
Eur J Cardiothorac Surg; 2007 Sep; 32(3):440-4. PubMed ID: 17643308
[TBL] [Abstract][Full Text] [Related]
33. Skip mediastinal nodal metastases in non-small cell lung cancer.
Tanaka F; Takenaka K; Oyanagi H; Fujinaga T; Otake Y; Yanagihara K; Ito H; Wada H
Eur J Cardiothorac Surg; 2004 Jun; 25(6):1114-20. PubMed ID: 15145018
[TBL] [Abstract][Full Text] [Related]
34. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.
Ichinose Y; Kato H; Koike T; Tsuchiya R; Fujisawa T; Shimizu N; Watanabe Y; Mitsudomi T; Yoshimura M; Tsuboi M;
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):803-8. PubMed ID: 11581617
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor.
Iwasaki A; Shirakusa T; Yoshinaga Y; Enatsu S; Yamamoto M
Eur J Cardiothorac Surg; 2004 Sep; 26(3):488-93. PubMed ID: 15302040
[TBL] [Abstract][Full Text] [Related]
36. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer.
Misthos P; Sepsas E; Kokotsakis J; Skottis I; Lioulias A
Ann Thorac Surg; 2008 Nov; 86(5):1626-30. PubMed ID: 19049761
[TBL] [Abstract][Full Text] [Related]
37. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer.
Varlotto JM; Recht A; Nikolov M; Flickinger JC; Decamp MM
Cancer; 2009 Feb; 115(4):851-8. PubMed ID: 19140203
[TBL] [Abstract][Full Text] [Related]
38. The prognostic impact of main bronchial lymph node involvement in non-small cell lung carcinoma: suggestions for a modification of the staging system.
Shimada Y; Tsuboi M; Saji H; Miyajima K; Usuda J; Uchida O; Kajiwara N; Ohira T; Hirano T; Kato H; Ikeda N
Ann Thorac Surg; 2009 Nov; 88(5):1583-8. PubMed ID: 19853116
[TBL] [Abstract][Full Text] [Related]
39. Preoperative serum value of sialyl Lewis X predicts pathological nodal extension and survival in patients with surgically treated small cell lung cancer.
Iwata T; Nishiyama N; Nagano K; Izumi N; Tsukioka T; Chung K; Hanada S; Inoue K; Kaji M; Suehiro S
J Surg Oncol; 2012 Jun; 105(8):818-24. PubMed ID: 22170474
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
